



FEE TRANSMITTAL
for FY 2005
(Large Entity)

Complete if Known	
Patent Number	6,451,534
Issue Date	17 September 2002
First Named Inventor	Mark T. Keating
Examiner Name	RECEIVED
Group Art Unit	OCT 31 2005
<input type="checkbox"/> Applicant claims small entity status	Attorney Docket Number
Total Amount of Payment	(\$130)
Confirmation Number	

NOV 04 2005
TECH CENTER 1600/2900
RECEIVED
OCT 31 2005
OFFICE OF PETITIONS

METHOD OF PAYMENT (check one)

- The Commissioner is hereby authorized to charge the fees indicated below or credit overpayment to Deposit Account Number 02-2135 in the name of Rothwell, Figg, Ernst & Manbeck
- Charge any additional fee required under 37 CFR 1.16 and 1.17 to Deposit Account No. 02-2135.
- Payment by check enclosed

FEES CALCULATION

1. FILING, SEARCH AND EXAMINATION FEES

Code	Fee	Fee Description	Fee Paid
1001	300	Utility Filing Fee	[]
1111	500	Utility Search Fee	[]
1311	200	Utility Examination Fee	[]
1002	200	Design Filing Fee	[]
1112	100	Design Search Fee	[]
1312	130	Design Examination Fee	[]
1003	200	Plant Filing Fee	[]
1113	300	Plant Search Fee	[]
1313	160	Plant Examination Fee	[]
1004	300	Reissue Filing Fee	[]
1114	500	Reissue Search Filing Fee	[]
1314	600	Reissue Examination Fee	[]
1005	200	Provisional Filing Fee	[]

SUBTOTAL \$

2. CLAIMS

		Extra Claims	Fee	Fee Paid
Total Claims	[]	- 20* = []	x \$50 = []	
Independent Claims	[]	- 3* = []	x 200 = []	
Multiple Dependent Claims	[]	+ 360 = []		

*or number previously paid, if greater


SUBTOTAL \$

3. APPLICATION SIZE FEE

Total Sheets [] - 100 = []/50 = []** x \$250 =
** Number of each additional 50 or fraction thereof

SUBTOTAL \$130

SUBTOTAL \$

SUBMITTED BY		Complete (if applicable)		
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Reg. No. 28,957			
SIGNATURE		DATE	27 October 2005	DEPOSIT ACCOUNT USER ID 02-2135
				XXX



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534 Confirmation No. 6467
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Docket No. : 2323-151
Customer No. : 6449

Mail Stop Petition
Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

RECEIVED

OCT 3 1 2005

OFFICE OF PETITIONS

***PETITION FOR CORRECTION OF
INVENTORSHIP PURSUANT TO 37 C.F.R. 1.324***

Sir:

Pursuant to the provisions of 37 C.F.R. §1.324(a), Applicants hereby petition for correction of inventorship in the subject Patent. Specifically, Applicants request the Commissioner to add QING WANG as co-inventor with the already-named inventors of record, Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn and Igor Splaswki.

In support of this petition, and in accordance with the requirements of 37 C.F.R. §1.324(b), Applicants concurrently submit the following:

- a *Statement under 37 C.F.R. §1.324(b)(1)*, signed by the inventor to be added;
- a *Statement under 37 C.F.R. §1.324(b)(2)*, signed by the current inventors;
- a *Consent of Assignee to Correct Inventorship*, by an authorized signatory of University of Utah Research Foundation, the assignee of the entire interest of Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Igor Splawski and Qing Wang in the subject Patent;
- a *Statement Pursuant to 37 C.F.R. §3.73(b)*, by an authorized signatory of assignee University of Utah Research Foundation; and


RECEIVED
NOV 04 2005
TECH CENTER 1600/2900

U.S. Patent No. 6,451,534
Petition for Correction of Inventorship
Pursuant to 37 C.F.R. 1.324

- a *Consent of Assignee to Correct Inventorship*, signed by an official of Genzyme Corporation, the assignee of the entire interest of co-inventors Gregory M. Landes, Timothy D. Connors and Timothy C. Burn in the subject Patent;
- a *Statement under 37 C.F.R. §3.73(b)* by assignee Genzyme Corporation;
- a check for the requisite \$130.00 fee.

If any additional payment is required, or any discrepancies in fees are noted, please charge or credit the cost thereof to Deposit Account No. 02-2135. An extra copy of this Request is attached for that purpose.

Respectfully submitted,

By 

Jeffrey V. Phien, Registration No. 28,957
Attorney for Applicants
ROTHWELL, FIGG, ERNST & MANBECK, P.C.
Suite 800, 1425 K Street, N.W.
Washington, D.C. 20005
Telephone: (202)783-6040

2323\..151.RCI.wpd



TRANSMITTAL FORM
(to be used for all correspondence after initial filing)

Complete if Known

Patent Number 6,451,534

Issue Date 17 September 2002

First Named Inventor Mark T. Keating

Examiner Name

Group Art Unit

Total Number of Pages in This Submission

Attorney Docket Number 2323-151

TECH CENTER 1600/2900

NOV 04 2005


ENCLOSURES (check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form	<input checked="" type="checkbox"/> Assignment Papers	<input type="checkbox"/> After Allowance Communication to Group
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input checked="" type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<ul style="list-style-type: none"> • Petition for Correction of Inventorship Pursuant to 37 C.F.R. §1.324 • Statement Under 37 C.F.R. §1.324(b)(1) • Statement Under 37 C.F.R. §1.324(b)(2) • Consent of Assignee to Correct Inventorship - University of Utah Statement Under 37 C.F.R. §3.73(b) - University of Utah • Consent of Assignee to Correct Inventorship - Genzyme Corporation Statement Under 37 C.F.R. §3.73(b) - Genzyme Corporation
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s)	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

REMARKS:
RECEIVED

OCT 31 2005

OFFICE OF PETITIONS

SUBMITTED BY		Complete (if applicable)		
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Reg. No. 28,957			
SIGNATURE		DATE	27 October 2005	DEPOSIT ACCOUNT USER ID 02-2135
				XXX



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534 Confirmation No. 6467
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Docket No. : 2323-151
Customer No. : 6449

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450


STATEMENT UNDER 37 C.F.R. § 1.324 (b)(1)

Sir:

QING WANG hereby states that he is a joint inventor of the invention of the above-identified Patent filed in the name of Mark T. Keating et al.

The application for the above-identified patent was inadvertently filed omitting the name of QING WANG as co-inventor, through error and without any deceptive intention on my part.

Date: Oct 19, 2004



Qing Wang

RECEIVED
NOV 04 2005
TECH CENTER 1600/2900



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534 Confirmation No. 6467
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Docket No. : 2323-151
Customer No. : 6449

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

RECEIVED

OCT 31 2005

STATEMENT PURSUANT TO 37 C.F.R. §3.73(b)

OFFICE OF PETITIONS

Sir:

UNIVERSITY OF UTAH RESEARCH FOUNDATION, through its undersigned signatory, who is authorized to sign on its behalf, represents that it is the assignee of the entire interest in the above-identified Patent with respect to the rights of coinventors Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Igor Splawski and Qing Wang, and that an assignment from the coinventors Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran and Igor Splawski to the University of Utah is recorded at Reel No. 009964, Frames 0732-0738 and an assignment to University of Utah Research Foundation from the University of Utah is recorded at Reel No. 009966, Frames 0867-0868. An assignment from the coinventor Qing Wang to the Howard Hughes Medical Institute, a Confirmation of Assignment from the Howard Hughes Medical Institute to the University of Utah and an assignment to the University of Utah Research Foundation from the University of Utah are being submitted for Patent Office recordation. A copy of these latter three assignments is attached.

UNIVERSITY OF UTAH RESEARCH FOUNDATION

Date: 10/6/04

By: Brent Brown
Brent Brown
Acting Director, Technology Transfer Office

RECEIVED
NOV 04 2005
TECH CENTER 1600/2900



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534
Patentee : Mark T. Keating et al.
Issued : 17 September 2002
Docket No. : 2323-151
Customer No. : 6449

Confirmation No. 6467

RECEIVED

NOV 04 2005

TECH CENTER 1600/2900

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

CONSENT OF ASSIGNEE TO CORRECT INVENTORSHIP

Sir:

UNIVERSITY OF UTAH RESEARCH FOUNDATION, assignee of the interest of the rights of Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Igor Splawski and Qing Wang in the subject matter of the Patent identified above, through its undersigned signatory, who is authorized to act on its behalf, hereby consents to correction of the inventorship of the subject Patent to add Qing WANG as co-inventor, along with the originally named inventors, Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn and Igor Splaswki.

UNIVERSITY OF UTAH RESEARCH FOUNDATION

Date: 10/06/04

By: Brent Brown
Brent Brown
Director, Technology Transfer Office

ASSIGNMENT

WHEREAS, UNIVERSITY OF UTAH, a non-profit organization duly organized under the laws of the State of Utah, with a place of business at 615 Arapeen Drive, Suite 110, Salt Lake City, Utah 84108 (hereinafter referred to as "Assignor") is the owner, by virtue of an assignment executed by co-inventor Qing WANG, of an invention in KVLQT1 - A LONG QT SYNDROME GENE, with regard to the following:

U.S. Patent 6,582,913, issued 24 June 2003;
 U.S. Patent 6,451,534, issued 17 September 2002;
 U.S. Patent 6,420,124, issued 16 July 2002;
 U.S. Patent 6,277,978, issued 21 August 2001; and
 U.S. Application Serial No. 10/368,643, filed 20 February 2003,

WHEREAS, UNIVERSITY OF UTAH RESEARCH FOUNDATION, incorporated in the state of Utah, with a place of business at 615 Arapeen Drive, Suite 110, Salt Lake City, Utah 84108, is desirous of obtaining the entire right, title and interest in, to and under the said inventions and the said applications;

NOW, THEREFORE, for good and valuable consideration, the receipt of which is hereby acknowledged, Assignor has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto the said UNIVERSITY OF UTAH RESEARCH FOUNDATION, its successors, legal representatives and assigns, the entire right, title and interest in, to and under the said invention, and the said patent and applications and all divisions, renewals and continuations thereof, and all Letters Patent of the United States which may be granted thereon and all reissues and extensions thereof, and all applications for Letters Patent which may hereafter be filed for said invention in any country or countries foreign to the United States, and all Letters Patent which may be granted for said invention in any country or countries foreign to the United States and all extensions, renewals and reissues thereof and all rights of priority in any such country or countries based upon the filing of the said patent and applications for Letters Patent of the United States which are created by any law, treaty or international convention; and Assignor hereby authorizes and requests the Commissioner of Patents of the United States, and any Official of any country or countries foreign to the United States, whose duty it is to issue patents on applications as aforesaid, to issue all Letters Patent for said invention to the said UNIVERSITY OF UTAH RESEARCH FOUNDATION, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants that it has full right to convey the entire interest herein assigned, and that it has not executed, and will not execute, any agreement in conflict herewith.

AND ASSIGNOR HEREBY further covenants and agrees that it will communicate to the said UNIVERSITY OF UTAH RESEARCH FOUNDATION, its successors, legal representatives and assigns, any facts known to it respecting said invention, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid the said UNIVERSITY OF UTAH RESEARCH FOUNDATION, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said invention in all countries.

IN TESTIMONY WHEREOF, Assignor sets its hand and seal the day and year set opposite its signature.

Date 10/06/04 2004 
 Brent Brown
 Director, Technology Transfer Office

L.S.

ASSIGNMENT

Assignment made July 7, 2004, by Qing Wang, PhD ("Inventor") to the Howard Hughes Medical Institute, a Delaware corporation (the "Institute").

Recitals

WHEREAS, Inventor was an employee of the Institute and, as a condition of his employment, has signed the Agreement appended to the Institute's Policy on Intellectual Property (the "Intellectual Property Agreement");

WHEREAS, pursuant to the Intellectual Property Agreement, Inventor has agreed (a) to assign to the Institute all rights he may acquire in any invention, discovery, improvement, or other intellectual property, whether or not patentable or copyrightable, developed directly or indirectly as a result of a program of research financed by Institute funds or funds under the control of the Institute (each a "Subject Property") and (b) to execute any agreements that may be desired by the Institute in connection with such assignment;

WHEREAS, Inventor has, alone or with others invented "KVLQT1 - A Long QT Syndrome Gene Which Encodes KVLQT1 Which Coassembles With minK to Form Cardiac IKS Potassium Channels" which may be the subject of a patent application (the "Invention"), and the Invention is a Subject Property; and

WHEREAS, Inventor seeks to make a formal assignment of his interest in the Invention to the Institute, and the Institute desires the execution of a formal assignment of all of Inventor's right, title, and interest in the Invention.

NOW, THEREFORE, in consideration of the promises contained in and the acts performed and to be performed pursuant to the Intellectual Property Agreement and of other good and valuable consideration, the receipt of which is hereby acknowledged by Inventor, Inventor agrees as follows:


1. Assignment. Inventor hereby assigns to the Institute his entire right, title, and interest in the Invention; any United States patent applications and all corresponding foreign patent applications which are directed to the Invention (including, without limitation, the patent application and patents listed on Exhibit A), and any and all patents issued therefrom; all United States or foreign division and continuation applications based on any of the foregoing, and any and all patents issued therefrom; and all claims which are directed to the Invention and which may be contained in continuation-in-part applications or in patents which issue therefrom.

2. Cooperation. Inventor agrees to execute upon request such further assignments, documents, and other instruments as may be necessary or desirable to assign Inventor's entire right, title and interest in the Invention to the Institute and to assist the Institute (or others at the direction of the Institute) in applying for, obtaining, and enforcing patents, copyrights, or other rights in the United States and in any foreign country with respect to the Invention.

3. Parties. The terms and provisions of the Assignment shall inure to the benefit of the Institute and its successors and assigns and shall be binding on the Inventor and his heirs, personal representatives and assigns.

4. Warranty. Inventor warrants and represents that he has not entered into any assignment, contract, or understanding in conflict herewith, and that there is no other person or entity whose consent is required in order for the Inventor to make the assignment contained herein.

Inventor:



Qing Wang, PhD

State of Ohio

County of Cuyahoga

Then personally appeared before me the above-named Qing Wang, PhD and acknowledged that he executed the foregoing instrument in his authorized capacity this 7th day of July, 2004

Notary Public: Carol J. Torre

CAROL J. TORRE

(print name)

My Commission Expires: _____

CAROL J. TORRE
Notary Public - State of Ohio
My Commission Expires May 13, 2006

U-2241
HHMI 00987

Exhibit A

Invention Title	Patent Number	Filing Date/Issue Date
KVLQT1-A Long QT Syndrome Gene	6,582,913	June 24, 2003
KVLQT1-A Long QT Syndrome Gene	6,451,534	September 17, 2002
KVLQT1-A Long QT Syndrome Gene	6,420,124	July 16, 2002
KVLQT1-A Long QT Syndrome Gene	6,277,978	August 21, 2001
KVLQT1-A Long QT Syndrome Gene	10/368,643	February 20, 2003

CONFIRMATION OF ASSIGNMENT

Confirmation of Assignment by Howard Hughes Medical Institute (the "Institute") to University of Utah ("University"), through Mark T. Keating, MD, an investigator employed by the Institute.

WHEREAS, the Institute and the University collaborate in the active conduct of medical research pursuant to a Collaboration Agreement between them dated as of October 1, 1986 (the "Collaboration Agreement");

WHEREAS, pursuant to the Collaboration Agreement, the Institute has agreed to assign to the University the Institute's rights with respect to inventions, discoveries, improvements, and other intellectual property, whether patentable or copyrightable (each a "subject property"), conceived or reduced to practice in the course of the research program conducted under the Collaboration Agreement by employees of the Institute;

WHEREAS, research conducted pursuant to the Collaboration Agreement by Dr. Keating while employed at the University by the Institute resulted in the invention of a certain subject property with respect to which patent applications were filed (the "Invention") (See Attachment 1); and


WHEREAS, in connection with the pursuit of the patent application, it is desirable to confirm that the Institute's rights in the Invention by reason of the research program conducted at the University have been validly assigned to the University by and through the assignments made by Dr. Keating listed in Attachment 1.

NOW, THEREFORE, the Institute hereby confirms that the Institute's rights in the Invention by reason of the research program conducted at the University have been validly assigned to the University by and through the assignments made by Dr. Keating listed in Attachment 1.

Executed 4/15/01


HOWARD HUGHES MEDICAL INSTITUTE

By:


Gerald M. Rubin, PhD
Vice President for Biomedical Research

ATTESTED:

By:


Joan S. Leonard
Vice President and General Counsel

U-2477
HHMI 1892

Assignments Associated with U-2477/HHMI 1892

HHMI Investigator	Patent Application Title	Filing Date	Application Number	Assignment Date
Mark T. Keating	Mutations in the KCNE1 Gene Encoding Human minK Which Cause Arrhythmia Susceptibility Thereby Establishing KCNE1 as an LQT Gene	8/29/97	08/921,068	3/16/1998
Mark T. Keating	Mutations in the KCNE1 Gene Encoding Human minK Which Cause Arrhythmia Susceptibility Thereby Establishing KCNE1 as an LQT Gene	8/17/98	09/135,020	10/7/98
Mark T. Keating	KVLQT1 - A Long QT Syndrome Gene	8/17/98	09/135,010	4/27/99



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534
Patentee : Mark T. Keating et al.
Issued : 17 September 2002
Docket No. : 2323-151
Customer No. : 6449

Confirmation No. 6467

RECEIVED

NOV 04 2005

TECH CENTER 1600/2900

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.324 (b)(2)

Sir:

MARK T. KEATING, MICHAEL C. SANGUINETTI, MARK E. CURRAN, GREGORY M. LANDES, TIMOTHY D. CONNORS, TIMOTHY C. BURN AND IGOR SPLASWKI hereby state that they agree with the requested change in inventorship.

Date: _____

Mark T. KEATING


Date: _____

Michael C. SANGUINETTI

Date: _____

Mark C. CURRAN

Date: 3/26/04


Gregory M. LANDES

Date: _____

Timothy D. CONNORS

Date: _____

Timothy C. BURN

Date: _____

Igor SPLAWSKI



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534
Patentee : Mark T. Keating et al.
Issued : 17 September 2002
Docket No. : 2323-151
Customer No. : 6449

Confirmation No. 6467

RECEIVED
NOV. 04 2005

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

TECH CENTER 1600/2900

STATEMENT UNDER 37 C.F.R. § 1.324 (b)(2)

Sir:

MARK T. KEATING, MICHAEL C. SANGUINETTI, MARK E. CURRAN, GREGORY M. LANDES, TIMOTHY D. CONNORS, TIMOTHY C. BURN AND IGOR SPLASWKI hereby state that they agree with the requested change in inventorship.

Date: _____

Mark T. KEATING

Date: _____

Michael C. SANGUINETTI

Date: _____

Mark C. CURRAN

Date: _____

Gregory M. LANDES

Date: 3/24/04

Timothy D. CONNORS

Date: _____

Timothy C. BURN

Date: _____

Igor SPLAWSKI



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534 Confirmation No. 6467
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Docket No. : 2323-151
Customer No. : 6449

RECEIVED
NOV 04 2005

TECH CENTER 1600/2800

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.324 (b)(2)

Sir:

MARK T. KEATING, MICHAEL C. SANGUINETTI, MARK E. CURRAN, GREGORY M. LANDES, TIMOTHY D. CONNORS, TIMOTHY C. BURN AND IGOR SPLAWSKI hereby state that they agree with the requested change in inventorship.

Date: _____

Mark T. KEATING

Date: _____

Michael C. SANGUINETTI

Date: _____

Mark C. CURRAN

Date: _____

Gregory M. LANDES

Date: _____

Timothy D. CONNORS

Date: 03/29/04

Timothy C. BURN

Timothy C. BURN

Date: _____

Igor SPLAWSKI



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534 Confirmation No. 6467
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Docket No. : 2323-151
Customer No. : 6449

RECEIVED

NOV 04 2005

TECH CENTER 1600/2900

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

STATEMENT UNDER 37 C.F.R. § 1.324 (b)(2)

Sir:


MARK T. KEATING, MICHAEL C. SANGUINETTI, MARK E. CURRAN,
GREGORY M. LANDES, TIMOTHY D. CONNORS, TIMOTHY C. BURN AND IGOR
SPLASWKI hereby state that they agree with the requested change in inventorship.

Date: _____

Mark T. KEATING

Date: _____

Michael C. SANGUINETTI



Date: _____

Mark E. CURRAN

Date: _____

Gregory M. LANDES

Date: _____

Timothy D. CONNORS

Date: _____

Timothy C. BURN

Date: _____

Igor SPLAWSKI



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534
Patentee : Mark T. Keating et al.
Issued : 17 September 2002
Docket No. : 2323-151
Customer No. : 6449

Confirmation No. 6467

RECEIVED

NOV 04 2005

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

TECH CENTER 1600/2900

STATEMENT UNDER 37 C.F.R. § 1.324 (b)(2)

Sir:

MARK T. KEATING, MICHAEL C. SANGUINETTI, MARK E. CURRAN, GREGORY M. LANDES, TIMOTHY D. CONNORS, TIMOTHY C. BURN AND IGOR SPLASWKI hereby state that they agree with the requested change in inventorship.

Date: 10/3/2005


Mark T. KEATING

Date: _____


Michael C. SANGUINETTI


Date: _____


Mark C. CURRAN

Date: _____


Gregory M. LANDES


Date: _____


Timothy D. CONNORS

Date: _____


Timothy C. BURN

Date: 10/3/2005


Igor SPLASWKI



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534 Confirmation No. 6467
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Docket No. : 2323-151
Customer No. : 6449

RECEIVED

NOV. 04 2005

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

TECH CENTER 1600/2900

STATEMENT UNDER 37 C.F.R. § 1.324 (b)(2)

Sir:

MARK T. KEATING, MICHAEL C. SANGUINETTI, MARK E. CURRAN, GREGORY M. LANDES, TIMOTHY D. CONNORS, TIMOTHY C. BURN AND IGOR SPLAWSKI hereby state that they agree with the requested change in inventorship.

Date: _____

Mark T. KEATING

Date: 2-June-2005

M. Sanguinetti

Michael C. SANGUINETTI

Date: _____

Mark C. CURRAN

Date: _____

Gregory M. LANDES

Date: _____

Timothy D. CONNORS

Date: _____

Timothy C. BURN

Date: _____

Igor SPLAWSKI



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Confirmation No. 6467

Docket No. : 2323-151
Customer No. : 6449

RECEIVED

NOV 04 2005

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

TECH CENTER 1600/2900

CONSENT OF ASSIGNEE TO CORRECT INVENTORSHIP

Sir:

GENZYME CORPORATION, assignee of the interest of the rights of Gregory M. Landes, Timothy D. Connors and Timothy C. Burn in the subject matter of the Patent identified above, through its undersigned signatory, who is authorized to act on its behalf, hereby consents to correction of the inventorship of the subject Patent to add Qing WANG as co-inventor, along with the originally named inventors, Mark T. Keating, Michael C. Sanguinetti, Mark E. Curran, Gregory M. Landes, Timothy D. Connors, Timothy C. Burn and Igor Splaswki.

GENZYME CORPORATION

Date: March 30, 2004

By: 

Name: Thomas J. DesRosier
Title: Senior VP, General Counsel
Chief Patent Counsel



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No. : 6,451,534
Patentee : Mark T. Keating et al.
Issued : 17 September 2002

Docket No. : 2323-151
Customer No. : 6449

Confirmation No. 6467

RECEIVED

NOV 04 2005

Director of the United States Patent
and Trademark Office
P.O. Box 1450
Alexandria, Virginia 22313-1450

TECH CENTER 1600/2900


STATEMENT PURSUANT TO 37 C.F.R. §3.73(b)

Sir:

GENZYME CORPORATION, through its undersigned signatory, who is authorized to sign on its behalf, represents that it is the assignee of the entire interest in the above-identified Patent with respect to the rights of coinventors Gregory M. Landes, Timothy D. Connors and Timothy C. Burn, and that an assignment from these coinventors to Genzyme Corporation is recorded at Reel No. 009966, Frames 0874-877.

GENZYME CORPORATION

Date: March 30, 2004

By: 

Name: Thomas J. DesRosier
Title: Senior VP, General Counsel
Chief Patent Counsel